ATP1B1
ENSG00000143153
Target class
Transporter
Chromosome
1
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- ATP1B1
- Gene name
- ATPase Na+/K+ transporting subunit beta 1
- Gene symbol
- ATP1B1
- Previous gene symbols
- ATP1B
- Protein name
- Sodium/potassium-transporting ATPase subunit beta-1 (Sodium/potassium-dependent ATPase subunit beta-1)
- Gene biotype
- Protein coding
- Gene family
- ATPase Na+/K+ transporting subunits
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 53
- Highest tissue expression
- 566
- Tissue specificity (Gini)
- 0.481
- Tissue specificity (tau)
- 0.774
- KEGG gene identifiers
- hsa:481
- Protein interaction confidence
- 0.852147
- Protein interaction partners
- 34
- R-HSA-210991
- R-HSA-5578775
- R-HSA-936837
- R-HSA-9679191
- End position
- 169310992
- Start position
- 169105697
- Chromosome
- 1
- Strand
- Forward
- Cell membrane
- Single-pass type II membrane protein . Apical cell membrane
- Single-pass type II membrane protein . Cell membrane, sarcolemma . Note=Colocalizes with OBSCN at the intercalated disk and sarcolemma in cardiomyocytes. Localizes in long striations at the level of Z and M lines. .
Publication evidence
- PubMed 34011520
- Tissue specificity (tau)
- 0.774082
- Expression inequality (Gini)
- 0.480777
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 566
- Kidney - Medulla
- 518.72
- Brain - Spinal cord (cervical c-1)
- 362.58
- Kidney - Cortex
- 349.7
- Brain - Cerebellar Hemisphere
- 328.39
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)566
- Kidney - Medulla518.72
- Brain - Spinal cord (cervical c-1)362.58
- Kidney - Cortex349.7
- Brain - Cerebellar Hemisphere328.39
- Brain - Hypothalamus311.61
- Thyroid282.47
- Stomach260.25
- Brain - Hippocampus257.24
- Brain - Anterior cingulate cortex (BA24)255.36
- Minor Salivary Gland222.23
- Brain - Substantia nigra217.96
- Brain - Cerebellum211.44
- Brain - Nucleus accumbens (basal ganglia)207.11
- Muscle - Skeletal201.53
- Brain - Cortex192.16
- Uterus189.84
- Brain - Caudate (basal ganglia)163.28
- Esophagus - Mucosa159.06
- Brain - Amygdala155.43
- Pituitary131.89
- Small Intestine - Terminal Ileum128.63
- Brain - Putamen (basal ganglia)122.96
- Colon - Transverse120.31
- Heart - Left Ventricle98.58
And 29 more, listed on the interactive page.
- GO:0006883
- GO:0010248
- GO:0030007
- GO:0035725
- GO:0044861
- GO:0046034
- GO:0050821
- GO:0072659
- GO:0086009
- GO:0086013
- GO:0086064
- GO:1903278
- GO:1903288
- GO:0005765
- GO:0005886
- GO:0005890
- GO:0016020
- GO:0016324
- GO:0016328
- GO:0030315
- GO:0031090
- GO:0036126
- GO:0070062
- GO:1903561
- GO:0001671
- GO:0005391
- GO:0005515
- GO:0023026
- GO:0030674
- GO:0051117
- GO:0141109
decreased heart rate
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased heart rate
- renal
- cardiovascular
PubMed 28216264increased urine excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urine excretion
- renal
- cardiovascular
PubMed 28216264atrioventricular block
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: atrioventricular block
- renal
- cardiovascular
PubMed 28216264vomiting
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: vomiting
- renal
- cardiovascular
PubMed 28216264increased cardiac contractility
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased cardiac contractility
- renal
- cardiovascular
PubMed 28216264cardiac arrhythmia
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: cardiac arrhythmia
- renal
- cardiovascular
PubMed 28216264increased urinary sodium excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urinary sodium excretion
- renal
- cardiovascular
PubMed 28216264ventricular fibrillation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: ventricular fibrillation
- renal
- cardiovascular
PubMed 28216264
Related records
Trials (335)
- 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
- A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
- A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)
- A Clinical Trial of Patients With Melanoma
- A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
- A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants
- A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
- A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants
- A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants
- A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
- A Drug Interaction Study of ACH-0145228
- A Drug Interaction Study of Albiglutide and Digoxin
- A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
- A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
- A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
- A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
- A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
Drugs (6)
- Acetyldigitoxin Sodium/potassium-transporting ATPase inhibitor
- Deslanoside Sodium/potassium-transporting ATPase inhibitor
- Digitoxin Sodium/potassium-transporting ATPase inhibitor
- Digoxin Sodium/potassium-transporting ATPase inhibitor
- Istaroxime Sodium/potassium-transporting ATPase inhibitor
- Lanatoside C Sodium/potassium-transporting ATPase inhibitor